1. Home
  2. CINGW vs FDSB Comparison

CINGW vs FDSB Comparison

Compare CINGW & FDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • FDSB
  • Stock Information
  • Founded
  • CINGW N/A
  • FDSB 1926
  • Country
  • CINGW United States
  • FDSB United States
  • Employees
  • CINGW 13
  • FDSB N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • FDSB
  • Sector
  • CINGW Health Care
  • FDSB
  • Exchange
  • CINGW Nasdaq
  • FDSB NYSE
  • Market Cap
  • CINGW N/A
  • FDSB N/A
  • IPO Year
  • CINGW 2021
  • FDSB N/A
  • Fundamental
  • Price
  • CINGW $0.04
  • FDSB $12.08
  • Analyst Decision
  • CINGW
  • FDSB
  • Analyst Count
  • CINGW 0
  • FDSB 0
  • Target Price
  • CINGW N/A
  • FDSB N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • FDSB 3.6K
  • Earning Date
  • CINGW N/A
  • FDSB 05-15-2025
  • Dividend Yield
  • CINGW N/A
  • FDSB N/A
  • EPS Growth
  • CINGW N/A
  • FDSB N/A
  • EPS
  • CINGW N/A
  • FDSB N/A
  • Revenue
  • CINGW N/A
  • FDSB $10,664,000.00
  • Revenue This Year
  • CINGW N/A
  • FDSB N/A
  • Revenue Next Year
  • CINGW N/A
  • FDSB N/A
  • P/E Ratio
  • CINGW N/A
  • FDSB N/A
  • Revenue Growth
  • CINGW N/A
  • FDSB N/A
  • 52 Week Low
  • CINGW N/A
  • FDSB $9.85
  • 52 Week High
  • CINGW N/A
  • FDSB $14.50
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • FDSB N/A
  • Support Level
  • CINGW N/A
  • FDSB N/A
  • Resistance Level
  • CINGW N/A
  • FDSB N/A
  • Average True Range (ATR)
  • CINGW 0.00
  • FDSB 0.00
  • MACD
  • CINGW 0.00
  • FDSB 0.00
  • Stochastic Oscillator
  • CINGW 0.00
  • FDSB 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: